Breaking News

Absorption Systems Registers as U.S. Generic Facility

March 27, 2013

Anticipates FDA registration for Panama ops

Absorption Systems has registered with the U.S. FDA as a generic drug facility under the Generic Drug User Fee Amendments of 2012 (GDUFA), which requires the company to be a Biopharmaceutics Classification System (BCS), bioequivalence (BE), and bioavailability (BA) testing facility. Additionally, the company’s Panama operation will be registered under GDUFA in the 2H13.
 
GDUFA authorizes the FDA to collect user fees from drug sponsors for marketing applications, NDAs for a branded drug, or ANDA for a generic drug. In exchange, a time limit is imposed on the agency's review of each application. Absorption Systems will not be charged a facility fee under GDUFA, since it is not involved in manufacturing of final dosage forms, APIs or primary packaging.
 
Patrick Dentinger, president and chief executive officer of Absorption Systems, said, "The world is gradually realizing what a unique and reliable approach to accelerating product approval the BCS is. Whereas GDUFA is expected to reduce the backlog of generic reviews, the BCS eliminates unnecessary human testing and dramatically reduces both the time and cost of product approval."

blog comments powered by Disqus
  • 16th Annual $alary $urvey

    16th Annual $alary $urvey

    Tim Wright, Editor||June 3, 2015
    Welcome to Contract Pharma’s Sixteenth Annual Salary Survey! This year’s results are derived from more than 500 respondents f

  • Newsmakers: PCI

    Newsmakers: PCI

    Tim Wright, Editor||June 2, 2015
    PCI execs talk about the recent opening of the company’s new North American clinical facility, as well as other trends in the market

  • How Sterilization of Primary Packaging Influences the Results of E&L Studies

    How Sterilization of Primary Packaging Influences the Results of E&L Studies

    Thorsten Sogding, Daniel Canton, Daniel Haines, Uwe Rothhaar, SCHOTT Pharma Services ||June 2, 2015
    As the demands that are being placed on the quality and stability of medications continue to increase, the interactions that take place between the primary packaging container and filled drug product are becoming increasingly important